A Phase 2/3 interventional study of Dupilumab and Matching placebo in Dermatitis, Atopic, sponsored by Regeneron Pharmaceuticals. Completed at 48 sites in 4 countries. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2022-07-28.
Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 16th largest by enrollment, is one of 4 that started in 2017, is the only one in phase 2/3, and was the 16th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 6 Months to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals: 1 open now, 2 under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 12th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2017, is the only one in phase 2/3, and was the 17th registered.
Regeneron Pharmaceuticals’s Dermatitis, Atopic studies by the year they started, since 2011.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Regeneron Pharmaceuticals’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in participants 6 months to less than 6 years of age with moderate-to-severe atopic dermatitis (AD).
Part A (open-label, single-ascending-dose, sequential cohort phase 2 study):
Part B (randomized, double-blind, parallel-group, placebo-controlled phase 3 study):
Key Inclusion Criteria
Key Exclusion Criteria
Note: Other protocol defined Inclusion/ Exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Age cohort 1: ≥2 years old to \<6 years old Age cohort 2: ≥6 months to \<2 years old
Drug: Dupilumab
The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
Drug: Dupilumab
The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
Drug: Dupilumab
Drug: Matching placebo
Solution for injection, subcutaneous (SC)
Also known as: DUPIXENT®, REGN668, SAR231893
Solution for injection, subcutaneous (SC)
Part A: Maximum Observed Serum Concentration (Cmax) of Functional Dupilumab
Serum concentration of functional dupilumab was reported.
Time frame: Post-dose on Days 1, 3, 8, 18, and 29
Part A: Dose Normalized Maximum Observed Serum Concentration (Cmax/Dose) of Dupilumab
Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose. Cmax/dose was measured in Milligrams per Liter/Milligrams per Kilogram (\[mg/L\]/\[mg/kg\]).
Time frame: Post-dose on Days 1, 3, 8, 18, and 29
Part A: Time to Reach the Maximum Serum Concentration (Tmax) of Dupilumab
Tmax was obtained directly from the concentration versus time curve.
Time frame: Post-dose on Days 1, 3, 8, 18, and 29
Part A: Last Quantifiable Serum Concentration (Clast) of Dupilumab
Clast is the last measurable serum concentration of dupilumab.
Time frame: Post-dose on Days 1, 3, 8, 18, and 29
Part A: Time of the Last Quantifiable Serum Concentration (Tlast) of Dupilumab
Tlast was defined as the last time point with a measurable serum concentration of dupilumab.
Time frame: Post-dose on Days 1, 3, 8, 18, and 29
Part A: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) of Dupilumab
AUClast was defined as area under the serum concentration time-curve from zero to the last measured concentration.
Time frame: Post-dose on Days 1, 3, 8, 18, and 29
Part A: Dose Normalized Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast/Dose) of Dupilumab
Dose normalized AUClast was calculated by AUClast/dose.
Time frame: Post-dose on Days 1, 3, 8, 18, and 29
Part A: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. Serious AE (SAE) was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE was defined as AE starting/worsening after first intake of study drug. TEAEs included participants with both SAEs and non-SAEs. Number of participants with TEAEs is reported.
Time frame: Baseline up to Week 4
Part A: Number of Participants With TEAEs by Severity According to Qualitative Toxicity Scale
Severity of TEAEs were graded using Qualitative Toxicity Scale, as follows: Mild: Participant is aware of the event or symptom, but the event or symptom is easily tolerated; Moderate: Participant experiences sufficient discomfort to interfere with or reduce his or her usual level of activity; Severe: Significant impairment of functioning: the participant is unable to carry out his or her usual activities. Number of participants with TEAEs by severity were reported.
Time frame: Baseline up to Week 4
Part B: Percentage of Participants With Investigator's Global Assessment (IGA) Score 0 or 1 at Week 16
The IGA is an assessment scale used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 to 4 where 0 = clear; 1=almost clear; 2=mild; 3=moderate; 4=severe. A negative change from baseline indicated improvement. Percentage of participants with IGA score of '0' or '1' is reported.
Time frame: Week 16
Part B: Percentage of Participants With Eczema Area and Severity Index (EASI) -75 (EASI-75) (≥75% Improvement From Baseline) at Week 16
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline at Week 16.
Time frame: Week 16
Part A: Number of Participants With Serious TEAEs and Severe TEAEs
Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Severe TEAE: significant impairment of functioning the participant is unable to carry out his or her usual activities.
Time frame: Baseline up to Week 4
Part A: Percent Change From Baseline in EASI Score at Week 4
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicated the worse severity of AD. A negative change from baseline indicated improvement.
Time frame: Week 4
Part A: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 4
The SCORAD is used to assess the extent and severity of AD. Extent and severity of eczema as well as subjective symptoms (insomnia, etc) were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease). A negative change from baseline indicated improvement.
Time frame: Week 4
Part A: Percentage of Participants With IGA Score 0 or 1 at Week 4
The IGA is an assessment scale used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 to 4 where 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe. Percentage of participants with IGA score of '0' or '1' were reported.
Time frame: Week 4
Part A: Number of Participants With at Least One Positive Treatment-Emergent Anti-Drug Antibodies (ADA)
Treatment boosted (TB) Response: Any post-dose positive result at least 9-fold over the baseline level when baseline is positive; Treatment emergent (TE) Response: Post-dose positive result when baseline results were negative.
Time frame: Baseline up to Day 57
Part B: Number of Participants With at Least One Serious Adverse Event (SAE) Through Week 16
Time frame: Baseline through Week 16
Part B: Number of Participants With at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infection) Through Week 16
Time frame: Baseline through Week 16
Part B: Number of Participants With at Least One Positive Treatment-Emergent ADA
Treatment emergent (TE): Post-dose positive result when baseline results were negative.
Time frame: Baseline up to Day 197
Part B: Percent Change From Baseline in EASI Score at Week 16
The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. A negative change from baseline indicated improvement.
Time frame: Week 16
Part B: Percent Change From Baseline in Weekly Average of Daily Worst Scratch/Itch/Numerical Rating Scale (NRS) at Week 16
Pruritus NRS is an assessment tool used to report intensity of participant's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Participants were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable. A negative change from baseline indicated improvement.
Time frame: Week 16
Part B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥4 Points at Week 16
Pruritus NRS is an assessment tool used to report intensity of subject's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Subjects were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; \& 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable.
Time frame: Week 16
Part B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥3 Points at Week 16
Pruritus NRS is an assessment tool used to report intensity of participant's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Participants were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; \& 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable.
Time frame: Week 16
Part B: Percentage of Participants Who Achieved EASI-50 (≥50% Improvement From Baseline) at Week 16
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline at Week 16.
Time frame: Week 16
Part B: Percentage of Participants Who Achieved EASI-90 (≥90% Improvement From Baseline) at Week 16
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-90 responders were the participant who achieved ≥90% overall improvement in EASI score from baseline at Week 16.
Time frame: Week 16
Part B: Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. A negative change from baseline indicated improvement.
Time frame: Week 16
Part B: Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16
The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). A negative change from baseline indicated improvement.
Time frame: Week 16
Part B: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16
The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis (AD). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). A negative change from baseline indicated improvement.
Time frame: Week 16
Part B: Change From Baseline in Participant's Sleep Quality NRS at Week 16
A sleep diary is completed by the parent/caregiver, included 2 questions assessing the caregiver's sleep, and 6 questions assessing the child's sleep based on caregiver observation. Sleep diary items, either alone or in combination serve as subjective measures of sleep quality, difficulty falling asleep, nighttime awakenings, and sleep duration. Sleep quality is measured using an 11-point NRS (0 to 10) in which 0 indicates worst possible sleep while 10 indicates best possible sleep.
Time frame: Week 16
Part B: Change From Baseline in Participant's Skin Pain NRS at Week 16
Skin pain was assessed by the parent/caregiver and measured using a 11-point scale (0 to 10) in which 0 indicated no pain while 10 indicated worst pain possible. A negative change from baseline indicated improvement.
Time frame: Week 16
Part B: Change From Baseline in Dermatitis Family Index (DFI) at Week 16
DFI is a 10-item questionnaire with items inquiring about housework, food preparation, sleep, family leisure activity, shopping, expenditure, tiredness, emotional distress, relationships, and impact of helping with treatment on the primary caregiver's life. DFI questions were scored on a four-point Likert scale ranging from 0 to 3, so that the total DFI score ranges from 0 to 30. Timeframe of reference was the past week. A higher DFI score indicated greater impairment in family Quality of life (QOL) as affected by atopic dermatitis. A negative change from baseline indicated improvement.
Time frame: Week 16
Part B: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16
CDLQI is a validated 10 question tool to measure impact of skin disease on QOL in children by assessing how much the skin problem has affected the subjects over past week. Nine questions were scored as follows: Very much = 3, Quite a lot = 2, Only a little = 1, Not at all or unanswered = 0. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question (max. = 30, min. = 0). Higher the score, the greater the impact on QOL. A negative change from baseline indicated improvement.
Time frame: Week 16
Part B: Change From Baseline in Infants' Dermatology Quality of Life Index (IDQOL) at Week 16
Infants' Dermatitis Quality of Life Index (IDQOL) is used to evaluate quality of life for subjects of age less than 4 years. IDQOL questionnaires were designed for infants (below the age of 4 years) with atopic dermatitis. The IDQOL was calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score in each questionnaire, the more quality of life is impaired. A negative change from baseline indicated improvement.
Time frame: Week 16
Part B: Percentage of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 16
Percentage of TCS medication-free days was calculated as the number of days that a subject used neither TCS/TCI nor system rescue therapy divided by the study days.
Time frame: Baseline up to Week 16
Part B: Mean Weekly Dose of Low Potency TCS in Grams From Baseline to Week 16
Mean weekly dose of TCS in grams/week for low potency TCS from baseline to Week 16 is reported.
Time frame: Baseline up to Week 16
Part B: Mean Weekly Dose of TCS in Grams for Medium or High Potency TCS From Baseline to Week 16
Mean weekly dose of TCS in grams/week for medium or high potency TCS from baseline to Week 16 is reported.
Time frame: Baseline up to Week 16
Part B: Mean Number of Caregiver Missed Work Days Through Week 16
Mean of number of caregiver missed work days through Week 16 is reported.
Time frame: Baseline through Week 16
This study was conducted in 2 parts: Part A and Part B; Participants who enrolled in Part A of study were not eligible to participate in Part B.
| Milestone | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 79 | 83 |
| Completed part a | 10 | 10 | 9 | 10 | 0 | 0 |
| Completed part b (week 16) | 0 | 0 | 0 | 0 | 76 | 83 |
| Completed part b (week 28) | 0 | 0 | 0 | 0 | 1 | 1 |
| Completed | 10 | 10 | 9 | 10 | 1 | 1 |
| Not completed | 0 | 0 | 1 | 0 | 78 | 82 |
| Withdrew: Randomized in error | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Transitioned to ole study at week 16 (nct02612454) | 0 | 0 | 0 | 0 | 75 | 81 |
Serum concentration of functional dupilumab was reported.
| Milligrams per Liter (mg/L) | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Part A: Maximum Observed Serum Concentration (Cmax) of Functional Dupilumab | 25.2 ± 7.44 | 49.8 ± 11.3 | 20.1 ± 6.81 | 46.1 ± 11.1 |
Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose. Cmax/dose was measured in Milligrams per Liter/Milligrams per Kilogram (\[mg/L\]/\[mg/kg\]).
| [mg/L]/[mg/kg] | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Part A: Dose Normalized Maximum Observed Serum Concentration (Cmax/Dose) of Dupilumab | 8.39 ± 2.48 | 8.30 ± 1.89 | 6.70 ± 2.27 | 7.68 ± 1.86 |
Tmax was obtained directly from the concentration versus time curve.
| Days | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg |
|---|---|---|---|---|
| Part A: Time to Reach the Maximum Serum Concentration (Tmax) of Dupilumab | 1.97 ± 1.87 | 1.95 ± 1.75 | 2.10 ± 1.80 | 1.92 ± 1.72 |
Clast is the last measurable serum concentration of dupilumab.
| mg/L | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Part A: Last Quantifiable Serum Concentration (Clast) of Dupilumab | 6.64 ± 6.16 | 6.14 ± 4.69 | 5.64 ± 4.52 | 15.1 ± 9.48 |
Tlast was defined as the last time point with a measurable serum concentration of dupilumab.
| Days | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Part A: Time of the Last Quantifiable Serum Concentration (Tlast) of Dupilumab | 14.8 ± 6.79 | 26.5 ± 15.0 | 8.56 ± 6.88 | 16.0 ± 6.95 |
AUClast was defined as area under the serum concentration time-curve from zero to the last measured concentration.
| Days*Milligrams per Liter (day*mg/L) | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Part A: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) of Dupilumab | 198 ± 125 | 622 ± 184 | 123 ± 86.0 | 493 ± 294 |
Dose normalized AUClast was calculated by AUClast/dose.
| [day*mg/L]/[mg/kg] | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Part A: Dose Normalized Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast/Dose) of Dupilumab | 66.0 ± 41.6 | 104 ± 30.6 | 41.0 ± 28.7 | 82.1 ± 48.9 |
Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. Serious AE (SAE) was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE was defined as AE starting/worsening after first intake of study drug. TEAEs included participants with both SAEs and non-SAEs. Number of participants with TEAEs is reported.
| Participants | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Part A: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) | 3 | 2 | 7 | 7 |
Severity of TEAEs were graded using Qualitative Toxicity Scale, as follows: Mild: Participant is aware of the event or symptom, but the event or symptom is easily tolerated; Moderate: Participant experiences sufficient discomfort to interfere with or reduce his or her usual level of activity; Severe: Significant impairment of functioning: the participant is unable to carry out his or her usual activities. Number of participants with TEAEs by severity were reported.
| Participants | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Mild | 1 | 2 | 4 | 5 |
| Moderate | 2 | 0 | 2 | 2 |
| Severe | 0 | 0 | 1 | 0 |
The IGA is an assessment scale used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 to 4 where 0 = clear; 1=almost clear; 2=mild; 3=moderate; 4=severe. A negative change from baseline indicated improvement. Percentage of participants with IGA score of '0' or '1' is reported.
| Percentage of Participants | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Percentage of Participants With Investigator's Global Assessment (IGA) Score 0 or 1 at Week 16 | 3.9 ± -0.42 | 27.7 ± 18.45 |
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline at Week 16.
| Percentage of Participants | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Percentage of Participants With Eczema Area and Severity Index (EASI) -75 (EASI-75) (≥75% Improvement From Baseline) at Week 16 | 10.7 ± 3.65 | 53.0 ± 41.74 |
Adverse Event (AE) was defined as any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Severe TEAE: significant impairment of functioning the participant is unable to carry out his or her usual activities.
| Participants | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Participants with serious TEAEs | 1 | 0 | 1 | 0 |
| Participants with severe TEAEs | 0 | 0 | 1 | 0 |
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicated the worse severity of AD. A negative change from baseline indicated improvement.
| Percent Change | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Part A: Percent Change From Baseline in EASI Score at Week 4 | -26.6 ± 47.37 | -48.7 ± 28.89 | -22.4 ± 42.52 | -43.2 ± 35.55 |
The SCORAD is used to assess the extent and severity of AD. Extent and severity of eczema as well as subjective symptoms (insomnia, etc) were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease). A negative change from baseline indicated improvement.
| Percent Change | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Part A: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 4 | -18.6 ± 26.18 | -31.9 ± 17.45 | -22.4 ± 26.44 | -28.1 ± 27.84 |
The IGA is an assessment scale used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 to 4 where 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe. Percentage of participants with IGA score of '0' or '1' were reported.
| Percentage of Participants | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| Part A: Percentage of Participants With IGA Score 0 or 1 at Week 4 | 10.0 ± 0.25 | 0.0 ± 0.00 | 10.0 ± 0.25 | 10.0 ± 0.25 |
Treatment boosted (TB) Response: Any post-dose positive result at least 9-fold over the baseline level when baseline is positive; Treatment emergent (TE) Response: Post-dose positive result when baseline results were negative.
| Participants | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg |
|---|---|---|---|---|
| TB Response | 0 | 0 | 1 | 0 |
| TE Response | 5 | 4 | 5 | 5 |
| Participants | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Number of Participants With at Least One Serious Adverse Event (SAE) Through Week 16 | 4 | 0 |
| Participants | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Number of Participants With at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infection) Through Week 16 | 19 | 10 |
Treatment emergent (TE): Post-dose positive result when baseline results were negative.
| Participants | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Number of Participants With at Least One Positive Treatment-Emergent ADA | 0 | 1 |
The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. A negative change from baseline indicated improvement.
| Percent Change | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Percent Change From Baseline in EASI Score at Week 16 | -19.6 ± 5.13 | -70.0 ± 4.85 |
Pruritus NRS is an assessment tool used to report intensity of participant's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Participants were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable. A negative change from baseline indicated improvement.
| Percent Change | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Percent Change From Baseline in Weekly Average of Daily Worst Scratch/Itch/Numerical Rating Scale (NRS) at Week 16 | -2.2 ± 5.22 | -49.4 ± 5.03 |
Pruritus NRS is an assessment tool used to report intensity of subject's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Subjects were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; \& 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable.
| Percentage of Participants | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥4 Points at Week 16 | 8.9 ± 2.25 | 48.1 ± 37.05 |
Pruritus NRS is an assessment tool used to report intensity of participant's pruritus (itch), both average \& maximum intensity, during 24-hr recall period. Participants were asked two questions: 1) For average itch intensity: how would you rate your itch overall (on average) during the previous 24 hrs; \& 2) For maximum itch intensity: How would you rate your itch at the worst moment during the previous 24 hrs? Both questions were rated on a scale: 0-10 with 0=no itch \& 10=worst itch imaginable.
| Percentage of Participants | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Scratch/Itch/NRS ≥3 Points at Week 16 | 9.9 ± 2.59 | 53.3 ± 42.29 |
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline at Week 16.
| Percentage of Participants | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Percentage of Participants Who Achieved EASI-50 (≥50% Improvement From Baseline) at Week 16 | 20.2 ± 11.09 | 68.7 ± 57.56 |
The EASI score is used to measure the severity and extent of AD and measured erythema, infiltration, excoriation, and lichenification on 4 anatomic regions of the body: head, trunk, upper, and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicating the worse severity of AD. EASI-90 responders were the participant who achieved ≥90% overall improvement in EASI score from baseline at Week 16.
| Percentage of Participants | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Percentage of Participants Who Achieved EASI-90 (≥90% Improvement From Baseline) at Week 16 | 2.8 ± -1.02 | 25.3 ± 16.39 |
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. A negative change from baseline indicated improvement.
| Percentage of Body Surface Area (BSA) | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16 | -10.74 ± 2.926 | -35.00 ± 2.815 |
The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). A negative change from baseline indicated improvement.
| Score on a Scale | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16 | -3.8 ± 0.92 | -12.9 ± 0.89 |
The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis (AD). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). A negative change from baseline indicated improvement.
| Percent Change | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16 | -16.2 ± 3.54 | -54.7 ± 3.39 |
A sleep diary is completed by the parent/caregiver, included 2 questions assessing the caregiver's sleep, and 6 questions assessing the child's sleep based on caregiver observation. Sleep diary items, either alone or in combination serve as subjective measures of sleep quality, difficulty falling asleep, nighttime awakenings, and sleep duration. Sleep quality is measured using an 11-point NRS (0 to 10) in which 0 indicates worst possible sleep while 10 indicates best possible sleep.
| Score on a Scale | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Change From Baseline in Participant's Sleep Quality NRS at Week 16 | 0.34 ± 0.256 | 2.04 ± 0.251 |
Skin pain was assessed by the parent/caregiver and measured using a 11-point scale (0 to 10) in which 0 indicated no pain while 10 indicated worst pain possible. A negative change from baseline indicated improvement.
| Score on a Scale | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Change From Baseline in Participant's Skin Pain NRS at Week 16 | -0.62 ± 0.302 | -3.93 ± 0.295 |
DFI is a 10-item questionnaire with items inquiring about housework, food preparation, sleep, family leisure activity, shopping, expenditure, tiredness, emotional distress, relationships, and impact of helping with treatment on the primary caregiver's life. DFI questions were scored on a four-point Likert scale ranging from 0 to 3, so that the total DFI score ranges from 0 to 30. Timeframe of reference was the past week. A higher DFI score indicated greater impairment in family Quality of life (QOL) as affected by atopic dermatitis. A negative change from baseline indicated improvement.
| Score on a Scale | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Change From Baseline in Dermatitis Family Index (DFI) at Week 16 | -2.68 ± 0.839 | -10.48 ± 0.806 |
CDLQI is a validated 10 question tool to measure impact of skin disease on QOL in children by assessing how much the skin problem has affected the subjects over past week. Nine questions were scored as follows: Very much = 3, Quite a lot = 2, Only a little = 1, Not at all or unanswered = 0. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question (max. = 30, min. = 0). Higher the score, the greater the impact on QOL. A negative change from baseline indicated improvement.
| Score on a Scale | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16 | -2.5 ± 1.66 | -10.0 ± 1.56 |
Infants' Dermatitis Quality of Life Index (IDQOL) is used to evaluate quality of life for subjects of age less than 4 years. IDQOL questionnaires were designed for infants (below the age of 4 years) with atopic dermatitis. The IDQOL was calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score in each questionnaire, the more quality of life is impaired. A negative change from baseline indicated improvement.
| Score on a Scale | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Change From Baseline in Infants' Dermatology Quality of Life Index (IDQOL) at Week 16 | -1.95 ± 1.078 | -10.91 ± 1.159 |
Percentage of TCS medication-free days was calculated as the number of days that a subject used neither TCS/TCI nor system rescue therapy divided by the study days.
| Percentage of Days | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Percentage of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 16 | 0.04 ± 0.0 | 0.21 ± 0.0 |
Mean weekly dose of TCS in grams/week for low potency TCS from baseline to Week 16 is reported.
| Grams per Week | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Mean Weekly Dose of Low Potency TCS in Grams From Baseline to Week 16 | 13.4 ± 1.44 | 10.5 ± 1.39 |
Mean weekly dose of TCS in grams/week for medium or high potency TCS from baseline to Week 16 is reported.
| Grams per Week | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Mean Weekly Dose of TCS in Grams for Medium or High Potency TCS From Baseline to Week 16 | 6.1 ± 1.70 | 3.0 ± 1.54 |
Mean of number of caregiver missed work days through Week 16 is reported.
| Days | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|
| Part B: Mean Number of Caregiver Missed Work Days Through Week 16 | 5.05 ± 8.975 | 2.49 ± 5.524 |
Collected over From day of first treatment up to Week 28 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | 0/10 (0%) | 1/10 (10%) | 7/10 (70%) |
| Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | 0/10 (0%) | 1/10 (10%) | 3/10 (30%) |
| Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Part B: Placebo + TCS | 0/78 (0%) | 4/78 (5.1%) | 45/78 (57.7%) |
| Part B: Dupilumab 200 mg or 300 mg Q4W + TCS | 0/83 (0%) | 0/83 (0%) | 29/83 (34.9%) |
| Event | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|---|---|---|---|
| Anaphylactic reactionImmune system disorders | 1/10 | 0/10 | 1/10 | 0/10 | 0/78 | 0/83 |
| HypersensitivityImmune system disorders | 0/10 | 0/10 | 0/10 | 0/10 | 1/78 | 0/83 |
| Cellulitis staphylococcalInfections and infestations | 0/10 | 0/10 | 0/10 | 0/10 | 1/78 | 0/83 |
| Dermatitis infectedInfections and infestations | 0/10 | 0/10 | 0/10 | 0/10 | 1/78 | 0/83 |
| Staphylococcal bacteraemiaInfections and infestations | 0/10 | 0/10 | 0/10 | 0/10 | 1/78 | 0/83 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/10 | 0/10 | 0/10 | 0/10 | 1/78 | 0/83 |
| Event | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS |
|---|---|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/10 | 1/10 | 1/10 | 0/10 | 24/78 | 12/83 |
| NasopharyngitisInfections and infestations | 1/10 | 2/10 | 1/10 | 1/10 | 7/78 | 7/83 |
| PyrexiaGeneral disorders | 2/10 | 0/10 | 1/10 | 0/10 | 7/78 | 1/83 |
| Upper respiratory tract infectionInfections and infestations | 1/10 | 1/10 | 0/10 | 0/10 | 7/78 | 5/83 |
| ImpetigoInfections and infestations | 1/10 | 1/10 | 1/10 | 0/10 | 6/78 | 3/83 |
| FolliculitisInfections and infestations | 1/10 | 0/10 | 0/10 | 0/10 | 0/78 | 0/83 |
| UrticariaSkin and subcutaneous tissue disorders | 1/10 | 1/10 | 0/10 | 0/10 | 4/78 | 1/83 |
| ThrombocytosisBlood and lymphatic system disorders | 0/10 | 1/10 | 0/10 | 0/10 | 0/78 | 0/83 |
| ConstipationGastrointestinal disorders | 1/10 | 0/10 | 0/10 | 0/10 | 0/78 | 2/83 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 1/10 | 0/10 | 0/10 | 2/78 | 1/83 |
| Age, Customized(Participants) | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS | Total |
|---|---|---|---|---|---|---|---|
| 6 months - <2 years | 0 | 0 | 10 | 10 | 5 | 6 | 31 |
| ≥2 years and <6 years | 10 | 10 | 0 | 0 | 74 | 77 | 171 |
| Sex: Female, Male(Participants) | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 1 | 2 | 24 | 39 | 73 |
| Male | 6 | 7 | 9 | 8 | 55 | 44 | 129 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 2 | 2 | 9 | 11 | 29 |
| Not Hispanic or Latino | 7 | 8 | 8 | 8 | 70 | 72 | 173 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investigator Global Assessment (IGA)(Participants) | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg | Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg | Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg | Part B: Placebo + TCS | Part B: Dupilumab 200 mg or 300 mg Q4W + TCS | Total |
|---|---|---|---|---|---|---|---|
| IGA=3 (moderate) | 0 | 0 | 0 | 0 | 17 | 20 | 37 |
| IGA=4 (severe) | 10 | 10 | 10 | 10 | 62 | 63 | 165 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Jul 2021, 43 months.
Results were first posted in Jul 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab